Recent Updates
Recently added Catalysts
RGNX Positive Sentiment Score: 75/100

REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

Thursday, December 18, 2025 2 min read
Key Takeaway: REGENXBIO Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 10:30 a.m. PT in San Francisco. The live presentation can be accessed via their website, with an archived replay available for 30 days. REGENXBIO focuses on the curative potential of gene therapy, advancing a late-stage pipeline for various rare diseases. The event highlights the company's commitment to improving healthcare through innovative treatments.

Market Sentiment Analysis

POSITIVE FACTORS

  • REGENXBIO is showcasing its advancements in gene therapy at a prestigious conference.
  • The company has a robust late-stage pipeline targeting severe diseases.
  • Live webcast access allows for wider investor engagement.

Full Press Release Details

ROCKVILLE, Md., Dec. 18, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 44th Annual J.P. Morgan Healthcare Conference.
Presentation Details
Date and Time: Wednesday, January 14, 2026 at 10:30 a.m. PT
Location: Westin St. Francis, San Francisco, CA
A live webcast of the presentation can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Corporate Communications
George E. MacDougall
SOURCE REGENXBIO Inc.

21 %

more press release views with

Frequently Asked Questions

When is REGENXBIO presenting at the J.P. Morgan Conference?

REGENXBIO will present on January 14, 2026, at 10:30 a.m. PT.

Where will the presentation take place?

The presentation will be held at the Westin St. Francis, San Francisco, CA.

How can I access the live presentation?

The live webcast can be accessed via the Investors section on REGENXBIO's website.

What therapies is REGENXBIO developing?

REGENXBIO is developing gene therapies for Duchenne, MPS II, MPS I, and retinal diseases.

What is REGENXBIO's mission?

REGENXBIO aims to improve lives through the curative potential of gene therapy.

Tags: RGNX Viatris Investor Conferences Healthcare REGENXBIO gene therapy J.P. Morgan Healthcare Conference rare diseases
Last updated: Dec 18, 2025